Koers Enzon Pharmaceuticals, Inc. Other OTC
Aandelen
ENZN
US2939041081
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 26K 24,32K | Omzet 2023 | - | Marktkapitalisatie | 6,94 mln. 6,49 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | - 0 | Nettowinst (verlies) 2023 | 1 mln. 935K | EV/omzet 2022 | -1.103 x |
Nettoliquiditeiten 2022 | 46,98 mln. 43,94 mln. | Nettoliquiditeiten 2023 | 47,01 mln. 43,97 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-12,5
x | K/w-verhouding 2023 |
70,9
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 89,16% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 80 | 13-12-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Randolph Read
CHM | Chairman | 71 | 04-08-20 |
Director/Board Member | 67 | 01-07-22 | |
Jordan Bleznick
BRD | Director/Board Member | 68 | 04-08-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |